Global End Stage Renal Disease Market Size study, By Treatment (Transplant, Dialysis), By End-User (Research and academic institutes, Hospital and Clinics, Dialysis centers), and Regional Forecasts 2022-2028

Global End Stage Renal Disease Market Size study, By Treatment (Transplant, Dialysis), By End-User (Research and academic institutes, Hospital and Clinics, Dialysis centers), and Regional Forecasts 2022-2028

Global End Stage Renal Disease Market is valued at approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2028. End-stage renal disease is also known as end-stage kidney disease or kidney failure. This is a chronic condition in which an individual ceases functioning permanently, which requires a regular course of long-term dialysis or a kidney transplant to sustain life. The growing incidences of diabetes and hypertension, the rising number of patients suffering from chronic kidney disease, coupled with the emergence of technologically advanced products are the primary factors propelling the market demand across the globe. For instance, according to the International Diabetic Federation (IDF), in 2019, nearly 463 million adults (20-79 years) were suffering from diabetes, and the amount is projected to rise and reach around 700 million by 2045. Thereby, the rising incidences of diabetes are exhibiting a positive influence on the global market growth. However, the imposition of stringent regulatory policies for dialysis products and the high risk of complications hinders the market growth over the forecast period of 2022-2028. Also, the rising regulatory support and increasing healthcare expenditure are anticipated to act as catalyzing factors for the market demand during the forecast period.

The key regions considered for the global End Stage Renal Disease Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. Asia Pacific is the leading region across the world in terms of market share owing to the presence of well-established healthcare facilities and high prevalence of target diseases, coupled with the rising population. Whereas, Europe is anticipated to exhibit the highest CAGR over the forecast period 2022-2028. Factors such as the growing healthcare spending, and rising government initiatives & awareness campaigns for CKD, would create lucrative growth prospects for the End Stage Renal Disease Market across the European region.

Major market players included in this report are:
Nipro Corp.
Fresenius Medical Care AG & Co. KGaA
Baxter International, Inc.
Medtronic Plc
B. Braun Melsungen AG
Becton, Dickinson and Company
Asahi Kasei Medical Co., Ltd.
Cantel Medical
Nikkiso Co., Ltd.
JMS Co. Ltd.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Treatment:
Transplant
Dialysis
By End-User:
Research and academic institutes
Hospital and Clinics
Dialysis centers
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global End Stage Renal Disease Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

Nipro Corp.
Fresenius Medical Care AG & Co. KGaA
Baxter International, Inc.
Medtronic Plc
B. Braun Melsungen AG
Becton, Dickinson and Company
Asahi Kasei Medical Co., Ltd.
Cantel Medical
Nikkiso Co., Ltd.
JMS Co. Ltd.


Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.